Literature DB >> 18572318

Urotensin II evokes neurotransmitter release from rat cerebrocortical slices.

Tomoko Ono1, Yoko Kawaguchi, Mihoko Kudo, Tetsuya Kushikata, Eiji Hashiba, Hitoshi Yoshida, Tsuyoshi Kudo, Kenichi Furukawa, Stephen A Douglas, Remo Guerrini, Girolamo Calo', Kazuyoshi Hirota.   

Abstract

Urotensin II (UII) has been reported to modulate rapid eye movement (REM) sleep via activation of brainstem cholinergic neurons and REM sleep is regulated by locus coerleus (LC)-cerebrocortical noradrenergic neurons. We hypothesized that UII may activate LC-cerebrocortical noradrenergic neurons. To test this hypothesis, we have examined the effects of UII on norepinephrine release from rat cerebrocortical slices. In addition, the effect of the putative UT receptor antagonist [Pen(5), DTrp(7), Dab(8)]UII(4-11) (UFP-803) was assessed. We have compared this with other wakefulness-promoting neurotransmitters such as dopamine, glutamate, serotonin and histamine. We also studied the effects of UII and UFP-803 on intracellular Ca(2+) ([Ca(2+)]i) in HEK293 cells stably expressing rat UT receptor (HEK293-rUT cells). UII produced a time- (peaking at approximately 10 min following stimulation with 10nM) and concentration-dependent increase in norepinephrine release with pEC(50) and E(max) (% of basal) values of 8.78+/-0.17 (1.65 nM) and 138+/-2%, respectively. UII also evoked dopamine, serotonin and histamine release with similar pEC(50) values. UII increased glutamate release but only at high concentrations (<100 nM) and this failed to saturate. UII markedly increased [Ca(2+)](i) in HEK293-rUT cells in a concentration-dependent manner with pEC(50) of 8.26+/-0.24. The UT antagonist UFP-803 reversed both UII-increased norepinephrine release from the cerebrocortical slices (pK(B)=8.98) and [Ca(2+)](i) (pK(B)=8.87) in HEK293-rUT cells. Collectively these data suggest that UII evokes the release of norepinephrine via UT receptor activation and produces similar effects on other wakefulness-promoting neurotransmitters: these neurochemical actions of UII may be important for the control of the sleep-wake cycle.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18572318     DOI: 10.1016/j.neulet.2008.05.096

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  6 in total

Review 1.  A rat brain atlas of urotensin-II receptor expression and a review of central urotensin-II effects.

Authors:  Benjamin D Hunt; Leong L Ng; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-04-27       Impact factor: 3.000

2.  Lack of association between urotensin-II (UTS2) gene polymorphisms (Thr21Met and Ser89Asn) and migraine.

Authors:  Betül Ozan; Seniz Demiryürek; Muhammad Safdar; Yusuf Inanc; Abdullah Tuncay Demiryürek
Journal:  Bosn J Basic Med Sci       Date:  2017-08-20       Impact factor: 3.363

3.  Update on the urotensinergic system: new trends in receptor localization, activation, and drug design.

Authors:  David Chatenet; Thi-Tuyet M Nguyen; Myriam Létourneau; Alain Fournier
Journal:  Front Endocrinol (Lausanne)       Date:  2013-01-02       Impact factor: 5.555

4.  Dysregulation of gene expression in a lysosomal storage disease varies between brain regions implicating unexpected mechanisms of neuropathology.

Authors:  Michael K Parente; Ramona Rozen; Cassia N Cearley; John H Wolfe
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

5.  Evaluation of Endothelial Dysfunction in Bipolar Affective Disorders: Serum Endocan and Urotensin-II Levels.

Authors:  Elif Oral; Zekai Halici; Irfan Cinar; Elif Ozcan; Zerrin Kutlu
Journal:  Clin Psychopharmacol Neurosci       Date:  2019-05-31       Impact factor: 2.582

6.  Down-regulation of GABA(A) receptor via promiscuity with the vasoactive peptide urotensin II receptor. Potential involvement in astrocyte plasticity.

Authors:  Laurence Desrues; Thomas Lefebvre; Céline Lecointre; Marie-Thérèse Schouft; Jérôme Leprince; Vincent Compère; Fabrice Morin; François Proust; Pierrick Gandolfo; Marie-Christine Tonon; Hélène Castel
Journal:  PLoS One       Date:  2012-05-01       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.